Gluvilda M + 1000 Tablet SR is a combination oral antidiabetic medication containing Metformin 1000 mg and Vildagliptin 50 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner, contributing to improved postprandial and fasting blood glucose levels. The sustained-release formulation of Gluvilda M + 1000 Tablet SR ensures a gradual release of Metformin, enhancing gastrointestinal tolerability and improving patient compliance. This combination therapy is particularly beneficial for patients inadequately controlled on monotherapy or those requiring dual mechanisms to achieve optimal glycemic targets. It should be used as an adjunct to diet and exercise, with regular monitoring of blood glucose and renal function. Contraindications include renal impairment, metabolic acidosis, and hypersensitivity to components. Common adverse effects may include gastrointestinal disturbances and mild hypoglycemia. Gluvilda M + 1000 Tablet SR offers an effective and convenient option for comprehensive glycemic management in type 2 diabetes mellitus.